Black Box Biotechnology B B B Black BoxBiotechnology
Eloralintide 5 mg RESEARCH USE ONLY BLACK BOX BIOTECHNOLOGY · Elor

Eloralintide

Also known as: LY3841136 · Selective amylin receptor agonist
Metabolic & GLP-1 In stock Box of 10 vials 2 references

Selective, long-acting amylin receptor agonist with 48-week phase 2 data.

Available sizes

SKUPer vialPack
Elor 5 mg 10 vials / box

Order Eloralintide

Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.

Quote on Telegram Quote on Signal

Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.

Eloralintide is a selective, long-acting amylin receptor agonist designed to avoid the calcitonin-receptor activity of earlier amylin analogues. Preclinical characterisation describes potent, selective amylin-receptor engagement with once-weekly pharmacokinetics 2.

In a 48-week phase 2 trial, eloralintide produced dose-dependent weight change up to approximately −20% at the highest dose tested, with predominantly gastrointestinal adverse events 1.

At a glance

  • Selective amylin receptor agonist (Lilly)
  • Phase 2 results published in The Lancet (2025)
  • 5 mg vials
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
Form
Lyophilized powder
Purity
HPLC-verified — Certificate of Analysis available on request
Pack size
Box of 10 vials
Storage
Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.

Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.

  1. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643.
    doi:10.1016/S0140-6736(25)02155-5 PubMed 41207310
  2. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271.
    doi:10.1016/j.molmet.2025.102271 PubMed 41109426

Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.

Related

Often ordered together

More in Metabolic
Quote on Telegram